MINNEAPOLIS, Feb. 23, 2017 /PRNewswire/ -- Cogentix
Medical, Inc. (NASDAQ: CGNT), a medical device company that
develops, manufactures and markets innovative proprietary products
for the urology market, will release financial results for the
fourth quarter and fiscal year ended December 31, 2016 before the market open on
Thursday, March 9, 2017.
The Company will host a conference call and webcast to discuss
its financial results the same day on Thursday, March 9, 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). Darin Hammers, President and Chief Executive
Officer, will host the event along with Brett Reynolds, Chief Financial Officer.
Individuals wishing to participate in the conference call should
dial 877-303-1595 with the conference ID number 78544327. To access
a live webcast of the call, go to the investor relations section of
Cogentix Medical's website at ir.cogentixmedical.com.
An audio replay will be available for 30 days following the call
at 855-859-2056 with the conference ID number 78544327. An archived
webcast will also be available at ir.cogentixmedical.com.
About Cogentix Medical
Cogentix Medical, Inc.,
headquartered in Minnetonka,
Minnesota, with additional operations in New York, Massachusetts, The
Netherlands and the United
Kingdom, is a global medical device company. We design,
develop, manufacture and market products for flexible endoscopy
with our unique product lines featuring a streamlined visualization
system and proprietary sterile disposable microbial barrier, known
as PrimeSight, providing users with efficient and cost effective
endoscope turnover while enhancing patient safety. We also
commercialize the Urgent® PC Neuromodulation System, an FDA-cleared
device that delivers percutaneous tibial nerve stimulation (PTNS)
for the office-based treatment of overactive bladder (OAB). OAB is
a chronic condition that affects approximately 42 million U.S.
adults. The symptoms include urinary urgency, frequency and urge
incontinence. We also offer Macroplastique®, an injectable
urethral bulking agent for the treatment of adult female stress
urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on Cogentix Medical and our
products, please visit us at www.cogentixmedical.com. 'CGNT-G'
For Further Information:
Cogentix Medical, Inc.
Brett Reynolds, SVP and CFO
952-426-6152
EVC Group
Doug Sherk/Brian Moore (Investors)
415-652-9100/310-579-6199
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cogentix-medical-to-report-fourth-quarter-results-on-march-9-2017-300412805.html
SOURCE Cogentix Medical, Inc.